Hithanadura Janaka de Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hithanadura Janaka de Silva has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Madunil Anuk Niriella
Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
14 shared publications - Anuradha Supun Dassanayake
Colombo North Centre for Liver Disease, Faculty of Medicine University of Kelaniya Ragama Sri Lanka
11 shared publications - Arjuna Priyadarshin De Silva
Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
8 shared publications - Ranjan Premaratna
Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
6 shared publications - Anuradhani Kasturiratne
Affiliation Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
4 shared publications - Arunasalam Pathmeswaran
University of Kelaniya
4 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2694
The Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review
Liver fibrosis staging plays a key role in the prognosis and management of chronic liver disease. Liver biopsy remains the reference standard for fibrosis assessment but is limited by its invasiveness and risk of complications, while magnetic resonance elastography, though also considered a gold standard, is constrained by cost and limited availability. Ultrasound-based elastography techniques—vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), and two-dimensional shear wave elastography (2D SWE)—have emerged as accessible non-invasive alternatives. This narrative review aimed to summarize the principles, diagnostic performance, advantages, and limitations of these three techniques across a range of etiologies. A comprehensive literature search was conducted across Scopus, PubMed, Embase, CINAHL, the Cochrane Library, Informit, and the JBI Database of Systematic Reviews and Implementation Reports, covering January 2015 to February 2026. Search terms included “vibration-controlled transient elastography”, “point shear wave elastography”, “two-dimensional shear wave elastography”, “liver stiffness measurement”, “non-invasive assessment” and “chronic liver disease”. International guidelines, systematic reviews and meta-analyses, large observational cohort studies, and narrative reviews were included in the synthesis. VCTE, pSWE, and 2D SWE all demonstrated good diagnostic performance for detecting advanced fibrosis and cirrhosis across multiple etiologies. VCTE was the most extensively validated technique, with standardized cut-offs endorsed by major international guidelines. pSWE and 2D SWE showed comparable diagnostic accuracy and can be integrated into conventional ultrasound systems, enabling simultaneous structural and stiffness assessment, although validated cut-off values for these two techniques are not yet established in current guidelines, and absolute stiffness values are not directly interchangeable across techniques, manufacturers, or software versions. Obesity, inflammation, steatosis and recent food intake were identified as factors affecting measurement accuracy across all three techniques. Ultrasound-based elastography techniques offer effective, non-invasive alternatives to liver biopsy for fibrosis assessment. VCTE remains the most validated option despite cost and availability constraints, while pSWE and 2D SWE offer comparable accuracy with practical integration advantages. Future research should focus on standardizing cut-off values, addressing confounding factors, and combining elastography with biomarkers and AI-driven models.
- 24 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2694
Open AccessThe Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review
Liver fibrosis staging plays a key role in the prognosis and management of chronic liver disease. Liver biopsy remains the reference standard for fibrosis assessment but is limited by its invasiveness and risk of complications, while magnetic resonance elastography, though also considered a gold standard, is constrained by cost and limited availability. Ultrasound-based elastography techniques—vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), and two-dimensional shear wave elastography (2D SWE)—have emerged as accessible non-invasive alternatives. This narrative review aimed to summarize the principles, diagnostic performance, advantages, and limitations of these three techniques across a range of etiologies. A comprehensive literature search was conducted across Scopus, PubMed, Embase, CINAHL, the Cochrane Library, Informit, and the JBI Database of Systematic Reviews and Implementation Reports, covering January 2015 to February 2026. Search terms included “vibration-controlled transient elastography”, “point shear wave elastography”, “two-dimensional shear wave elastography”, “liver stiffness measurement”, “non-invasive assessment” and “chronic liver disease”. International guidelines, systematic reviews and meta-analyses, large observational cohort studies, and narrative reviews were included in the synthesis. VCTE, pSWE, and 2D SWE all demonstrated good diagnostic performance for detecting advanced fibrosis and cirrhosis across multiple etiologies. VCTE was the most extensively validated technique, with standardized cut-offs endorsed by major international guidelines. pSWE and 2D SWE showed comparable diagnostic accuracy and can be integrated into conventional ultrasound systems, enabling simultaneous structural and stiffness assessment, although validated cut-off values for these two techniques are not yet established in current guidelines, and absolute stiffness values are not directly interchangeable across techniques, manufacturers, or software versions. Obesity, inflammation, steatosis and recent food intake were identified as factors affecting measurement accuracy across all three techniques. Ultrasound-based elastography techniques offer effective, non-invasive alternatives to liver biopsy for fibrosis assessment. VCTE remains the most validated option despite cost and availability constraints, while pSWE and 2D SWE offer comparable accuracy with practical integration advantages. Future research should focus on standardizing cut-off values, addressing confounding factors, and combining elastography with biomarkers and AI-driven models.
- Open Access
- 29 July 2026
- Published by MDPI AG in Preprints.org
The Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review
Background: Liver fibrosis staging plays a key role in the prognosis and management of chronic liver disease. Liver biopsy remains the reference standard for fibrosis assessment but is limited by its invasiveness and risk of complications, while magnetic resonance elastography, though also considered a gold standard, is constrained by cost and limited availability. Ultrasound-based elastography techniques — vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), and two-dimensional shear wave elastography (2D SWE) — have emerged as accessible non-invasive alternatives. This narrative review aimed to summarise the principles, diagnostic performance, advantages, and limitations of these three techniques across a range of aetiologies. Methods: A comprehensive literature search was conducted across Scopus, PubMed, Embase, CINAHL, the Cochrane Library, Informit, and the JBI Database of Systematic Reviews and Implementation Reports, covering January 2015 to February 2026. Search terms included “vibration-controlled transient elastography,” “point shear wave elastography,” “two-dimensional shear wave elastography,” “liver stiffness measurement,” “non-invasive assessment,” and “chronic liver disease.” International guidelines, systematic reviews and meta-analyses, large observational cohort studies, and narrative reviews were included in the synthesis. Results: VCTE, pSWE, and 2D SWE all demonstrated good diagnostic performance for detecting advanced fibrosis and cirrhosis across multiple aetiologies. VCTE was the most extensively validated technique, with standardised cut-offs endorsed by major international guidelines. pSWE and 2D SWE showed comparable diagnostic accuracy and can be integrated into conventional ultrasound systems, enabling simultaneous structural and stiffness assessment, although validated cut-off values for these two techniques are not yet established in current guidelines. Obesity, inflammation, steatosis, and recent food intake were identified as factors affecting measurement accuracy across all three techniques. Conclusions: Ultrasound-based elastography techniques offer effective, non-invasive alternatives to liver biopsy for fibrosis assessment. VCTE remains the most validated option despite cost and availability constraints, while pSWE and 2D SWE offer comparable accuracy with practical integration advantages. Future research should focus on standardising cut-off values, addressing confounding factors, and combining elastography with biomarkers and AI-driven models.
- 29 July 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review
Background: Liver fibrosis staging plays a key role in the prognosis and management of chronic liver disease. Liver biopsy remains the reference standard for fibrosis assessment but is limited by its invasiveness and risk of complications, while magnetic resonance elastography, though also considered a gold standard, is constrained by cost and limited availability. Ultrasound-based elastography techniques — vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), and two-dimensional shear wave elastography (2D SWE) — have emerged as accessible non-invasive alternatives. This narrative review aimed to summarise the principles, diagnostic performance, advantages, and limitations of these three techniques across a range of aetiologies. Methods: A comprehensive literature search was conducted across Scopus, PubMed, Embase, CINAHL, the Cochrane Library, Informit, and the JBI Database of Systematic Reviews and Implementation Reports, covering January 2015 to February 2026. Search terms included “vibration-controlled transient elastography,” “point shear wave elastography,” “two-dimensional shear wave elastography,” “liver stiffness measurement,” “non-invasive assessment,” and “chronic liver disease.” International guidelines, systematic reviews and meta-analyses, large observational cohort studies, and narrative reviews were included in the synthesis. Results: VCTE, pSWE, and 2D SWE all demonstrated good diagnostic performance for detecting advanced fibrosis and cirrhosis across multiple aetiologies. VCTE was the most extensively validated technique, with standardised cut-offs endorsed by major international guidelines. pSWE and 2D SWE showed comparable diagnostic accuracy and can be integrated into conventional ultrasound systems, enabling simultaneous structural and stiffness assessment, although validated cut-off values for these two techniques are not yet established in current guidelines. Obesity, inflammation, steatosis, and recent food intake were identified as factors affecting measurement accuracy across all three techniques. Conclusions: Ultrasound-based elastography techniques offer effective, non-invasive alternatives to liver biopsy for fibrosis assessment. VCTE remains the most validated option despite cost and availability constraints, while pSWE and 2D SWE offer comparable accuracy with practical integration advantages. Future research should focus on standardising cut-off values, addressing confounding factors, and combining elastography with biomarkers and AI-driven models.
- Open Access
- 30 December 2024
- Published by Sri Lanka Journals Online in Journal of Desk Research Review and Analysis
- Vol. 2 (1) , 58-66
Improving Cardiovascular Risk Prediction of Sri Lankans using Artificial Intelligence
There are no CV risk prediction models derived from Sri Lankan cohorts. Therefore, the World Health Organization(WHO) risk charts developed for the Southeast Asia Region are being used to risk stratify Sri Lankans. However, Sri Lankans are quite different to some Southeast Asian countries and may not agree with Sri Lankans. Therefore, we aimed to develop a CV risk prediction model specific to a cohort of Sri Lankans. Using supervised machine learning of 10-year follow-up data of a randomly selected, population-based cohort of Sri Lankans, we developed a model to predict the 10-year risk of developing a cardiovascular event. We compared predictions of the new model at baseline in 2007 with the observed events in 2017 following a 10-year follow-up using receiver operating characteristic curves(ROC) to find the predictive performance. We compared the predictions of the new model and the currently used WHO risk charts. We selected 2596 Sri Lankans between 40 and 65 years old with no history of previous CV diseases (CVD) at recruitment and who had completed 10-year follow-ups. There were 179 hard CVDs recorded over the ten years. CVD included all cardiovascular deaths confirmed or presumed cases as mentioned in death certificates, non-fatal strokes, and physician-diagnosed non-fatal acute coronary syndromes, including elective percutaneous coronary interventions and coronary artery bypass grafts done on patients with symptomatic unstable angina. Any cardiac presentation except those mentioned here was excluded. Of 179 events, the ML-based model predicted 124; only 33 were predicted by the new model, while only 33 were predicted by 2019 WHO risk charts. The new ML-based model had 0.93 accuracy with an AUC-ROC of 0.74 ± 0.06. Machine learning of individual data of a Sri Lankan cohort improved CV risk prediction of Sri Lankans than using risk charts developed for an epidemiological region using a modelling approach.
- 30 December 2024
- Published by Sri Lanka Journals Online in Journal of Desk Research Review and Analysis
- Vol. 2 (1) , 58-66
Open AccessImproving Cardiovascular Risk Prediction of Sri Lankans using Artificial Intelligence
There are no CV risk prediction models derived from Sri Lankan cohorts. Therefore, the World Health Organization(WHO) risk charts developed for the Southeast Asia Region are being used to risk stratify Sri Lankans. However, Sri Lankans are quite different to some Southeast Asian countries and may not agree with Sri Lankans. Therefore, we aimed to develop a CV risk prediction model specific to a cohort of Sri Lankans. Using supervised machine learning of 10-year follow-up data of a randomly selected, population-based cohort of Sri Lankans, we developed a model to predict the 10-year risk of developing a cardiovascular event. We compared predictions of the new model at baseline in 2007 with the observed events in 2017 following a 10-year follow-up using receiver operating characteristic curves(ROC) to find the predictive performance. We compared the predictions of the new model and the currently used WHO risk charts. We selected 2596 Sri Lankans between 40 and 65 years old with no history of previous CV diseases (CVD) at recruitment and who had completed 10-year follow-ups. There were 179 hard CVDs recorded over the ten years. CVD included all cardiovascular deaths confirmed or presumed cases as mentioned in death certificates, non-fatal strokes, and physician-diagnosed non-fatal acute coronary syndromes, including elective percutaneous coronary interventions and coronary artery bypass grafts done on patients with symptomatic unstable angina. Any cardiac presentation except those mentioned here was excluded. Of 179 events, the ML-based model predicted 124; only 33 were predicted by the new model, while only 33 were predicted by 2019 WHO risk charts. The new ML-based model had 0.93 accuracy with an AUC-ROC of 0.74 ± 0.06. Machine learning of individual data of a Sri Lankan cohort improved CV risk prediction of Sri Lankans than using risk charts developed for an epidemiological region using a modelling approach.
- Open Access
- 25 August 2023
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Infectious Diseases
- Vol. 13 (2)
The first reported case of co-infection of imported hepatitis E and Plasmodium falciparum malaria in Sri Lanka
Global travel and tourism, especially across tropical countries, may lead to importation of malaria and other infectious diseases into Sri Lanka. This case report describes the first co-infection of imported hepatitis E and Plasmodium falciparum malaria in a tourist diagnosed in Sri Lanka. The patient was initially diagnosed with uncomplicated P. falciparum malaria and was started on treatment with oral Artemisinin-based Combination Therapy (ACT). Deterioration of hepatic enzymes and hyperbilirubinaemia despite the rapid parasitological response to antimalarials led to further investigation and diagnosis of co-infecting hepatitis E in this patient. The importance of clinicians being vigilant on travel associated co-infections is highlighted to ensure early diagnosis and better patient management.
- 25 August 2023
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Infectious Diseases
- Vol. 13 (2)
Open AccessThe first reported case of co-infection of imported hepatitis E and Plasmodium falciparum malaria in Sri Lanka
Global travel and tourism, especially across tropical countries, may lead to importation of malaria and other infectious diseases into Sri Lanka. This case report describes the first co-infection of imported hepatitis E and Plasmodium falciparum malaria in a tourist diagnosed in Sri Lanka. The patient was initially diagnosed with uncomplicated P. falciparum malaria and was started on treatment with oral Artemisinin-based Combination Therapy (ACT). Deterioration of hepatic enzymes and hyperbilirubinaemia despite the rapid parasitological response to antimalarials led to further investigation and diagnosis of co-infecting hepatitis E in this patient. The importance of clinicians being vigilant on travel associated co-infections is highlighted to ensure early diagnosis and better patient management.
- Open Access
- 30 November 2021
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Surgery
- Vol. 39 (3) , 36-42
Fifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 2]
Globally, an estimated one million deaths occur annually due to complications of cirrhosis. Cirrhosis with end stage liver disease [ESLD] is a leading cause death due to noncommunicable diseases in Sri Lanka. Non-alcoholic fatty liver disease [NAFLD] and alcohol related liver disease [ARLD] are the principal causes of ESLD due to cirrhosis in Sri Lanka. Liver transplantation remains the only curative treatment for such patients. Multiorgan dysfunction and hemodynamic instability characteristic of ESLD adds to the complexity of perioperative care in liver transplantation. Maintenance of stable hemodynamics including optimal hemostasis forms the core of the anaesthetic strategy in liver transplantation.
- 30 November 2021
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Surgery
- Vol. 39 (3) , 36-42
Open AccessFifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 2]
Globally, an estimated one million deaths occur annually due to complications of cirrhosis. Cirrhosis with end stage liver disease [ESLD] is a leading cause death due to noncommunicable diseases in Sri Lanka. Non-alcoholic fatty liver disease [NAFLD] and alcohol related liver disease [ARLD] are the principal causes of ESLD due to cirrhosis in Sri Lanka. Liver transplantation remains the only curative treatment for such patients. Multiorgan dysfunction and hemodynamic instability characteristic of ESLD adds to the complexity of perioperative care in liver transplantation. Maintenance of stable hemodynamics including optimal hemostasis forms the core of the anaesthetic strategy in liver transplantation.
- Open Access
- 31 July 2021
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Surgery
- Vol. 39 (2) , 63-67
Fifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 1]
Cirrhosis with end stage liver disease (ESLD) is a leading cause of non-communicable disease related deaths in Sri Lanka. Liver transplantation is the only curative treatment for patients with ESLD. The complex multisystem involvement and unique cardiovascular profile characteristic of ESLD present formidable challenges during liver transplantation. Management of the rapid and varied hemodynamic changes during surgery requires an in depth understanding of the physiological effects of each intervention. Based on the current literature and the experience gained at our center during the management of 50 liver transplants, we present optimization strategies and perioperative hemodynamic interventions which we use to ‘Fast track’ recovery following liver transplantation.
- 31 July 2021
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Surgery
- Vol. 39 (2) , 63-67
Open AccessFifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 1]
Cirrhosis with end stage liver disease (ESLD) is a leading cause of non-communicable disease related deaths in Sri Lanka. Liver transplantation is the only curative treatment for patients with ESLD. The complex multisystem involvement and unique cardiovascular profile characteristic of ESLD present formidable challenges during liver transplantation. Management of the rapid and varied hemodynamic changes during surgery requires an in depth understanding of the physiological effects of each intervention. Based on the current literature and the experience gained at our center during the management of 50 liver transplants, we present optimization strategies and perioperative hemodynamic interventions which we use to ‘Fast track’ recovery following liver transplantation.
- Open Access
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
Introduction: Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a recently suggested alternative to Non-alcoholic fatty liver disease (NAFLD). We compared baseline metabolic traits and outcomes of NAFLD and MAFLD. Methods: In an ongoing, community-based, cohort study, participants were first screened in 2007 by structured-interview, anthropometry, liver ultrasonography, and biochemical/serological tests and reassessed after 7-years. Baseline characteristics and outcomes after 7-years were compared in NAFLD and MAFLD, in those excluded by the NAFLD definition but captured by the MAFLD definition and those excluded by the MAFLD definition but captured by the NAFLD definition, versus controls. Results: Of 2985 recruited in 2007, 940 (31.5%) had NAFLD, 990 (33.1%) had MAFLD and 362 (12.1%) were controls. Compared to NAFLD, MAFLD captured an additional 2.9% of individuals from the cohort and lost 1.3%. At baseline, anthropometric and metabolic traits were similar in NAFLD and MAFLD. At follow-up after 7 years, the odds of having new-onset metabolic traits and fatal/non-fatal CVEs were similar in the two groups, but were significantly higher in both the groups compared to controls. However, those excluded by the NAFLD definition but captured by the MAFLD definition, showed higher baseline metabolic derangements compared to those excluded by the MAFLD definition but captured by the NAFLD definition and had higher odds for having new onset metabolic traits and CVEs compared to controls. Conclusion: Even though it was able to increase the index population by only a small proportion, redefining NAFLD as MAFLD seemed to improve clinical utility. Lay Summary: The term “metabolic (dysfunction)-associated fatty liver disease (MAFLD)” has recently been suggested as an alternative to “non-alcoholic fatty liver disease (NAFLD)”. In our study, the diagnostic criteria for MAFLD detected a slightly higher number of individuals than NAFLD from the community. The proportions of anthropometric and metabolic abnormalities in NAFLD and MAFLD were similar. The adverse outcomes of NAFLD and MAFLD were also similar, but were worse than in a population without NAFLD or MAFLD. Those who were excluded by the NAFLD definition and captured by the MAFLD definition seem to be at higher risk of adverse outcomes than those excluded by the MAFLD definition but captured by the NAFLD definition. Although it was able to increase the index population by only a small proportion, redefining NAFLD as MAFLD seems useful.
Open AccessOutcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
Introduction: Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a recently suggested alternative to Non-alcoholic fatty liver disease (NAFLD). We compared baseline metabolic traits and outcomes of NAFLD and MAFLD. Methods: In an ongoing, community-based, cohort study, participants were first screened in 2007 by structured-interview, anthropometry, liver ultrasonography, and biochemical/serological tests and reassessed after 7-years. Baseline characteristics and outcomes after 7-years were compared in NAFLD and MAFLD, in those excluded by the NAFLD definition but captured by the MAFLD definition and those excluded by the MAFLD definition but captured by the NAFLD definition, versus controls. Results: Of 2985 recruited in 2007, 940 (31.5%) had NAFLD, 990 (33.1%) had MAFLD and 362 (12.1%) were controls. Compared to NAFLD, MAFLD captured an additional 2.9% of individuals from the cohort and lost 1.3%. At baseline, anthropometric and metabolic traits were similar in NAFLD and MAFLD. At follow-up after 7 years, the odds of having new-onset metabolic traits and fatal/non-fatal CVEs were similar in the two groups, but were significantly higher in both the groups compared to controls. However, those excluded by the NAFLD definition but captured by the MAFLD definition, showed higher baseline metabolic derangements compared to those excluded by the MAFLD definition but captured by the NAFLD definition and had higher odds for having new onset metabolic traits and CVEs compared to controls. Conclusion: Even though it was able to increase the index population by only a small proportion, redefining NAFLD as MAFLD seemed to improve clinical utility. Lay Summary: The term “metabolic (dysfunction)-associated fatty liver disease (MAFLD)” has recently been suggested as an alternative to “non-alcoholic fatty liver disease (NAFLD)”. In our study, the diagnostic criteria for MAFLD detected a slightly higher number of individuals than NAFLD from the community. The proportions of anthropometric and metabolic abnormalities in NAFLD and MAFLD were similar. The adverse outcomes of NAFLD and MAFLD were also similar, but were worse than in a population without NAFLD or MAFLD. Those who were excluded by the NAFLD definition and captured by the MAFLD definition seem to be at higher risk of adverse outcomes than those excluded by the MAFLD definition but captured by the NAFLD definition. Although it was able to increase the index population by only a small proportion, redefining NAFLD as MAFLD seems useful.
- Open Access
COVID-19 case forecasting model for Sri Lanka based on Stringency Index
Introduction Sri Lanka has been able to contain COVID-19 transmission through very stringent suppression measures implemented from the onset. The country had been under a strict lockdown since 20 March 2020, and currently the lockdown is being relaxed gradually. The objective of this paper is to describe a projection model for COVID-19 cases in Sri Lanka applied to different scenarios after lockout, utilizing the stringency index as a proxy of total government response. Methods COVID-19 Stringency Index (C19SI) is published and updated real time by a research group from Oxford university on 17 selected mitigation and suppression measures employed by different countries. We have mapped and validated the stringency index for Sri Lanka and subsequently validated the projection model in two phases. Predictions for the base-case scenario, less stringent scenarios, advanced relaxation scenarios, and high-risk districts were done with 95% confidence intervals (95%CI) using the validated model, utilizing data up to 10th May. Results C19SI was able to accommodate all of the government responses. The model using validated C19SI could predict number of cases with 95% confidence for a period of two weeks. The model predicted base-case scenario of 815 (95%CI, 753-877) active cases by 17 May 2020 and 648 (95%CI, 599-696) cases for the high-risk districts by 18 May 2020. The model further predicted 3,159 (95%CI, 2,928-3,391) cases for 75% stringency and 928,824 (95%CI, 861,772-995,877) cases for 50% stringency. Advancing normalcy by three weeks resulted in the case load increasing to 4526 (95%CI, 4309-4744) by 30 June 2020. Conclusion The proposed prediction model based on C19SI provides policy makers an evidence based scientific method for identifying suppression measures that can be relaxed at the most appropriate time. Key words: COVID-19, Projections, Stringency Index, SIR Model, Sri Lanka
Open AccessCOVID-19 case forecasting model for Sri Lanka based on Stringency Index
Introduction Sri Lanka has been able to contain COVID-19 transmission through very stringent suppression measures implemented from the onset. The country had been under a strict lockdown since 20 March 2020, and currently the lockdown is being relaxed gradually. The objective of this paper is to describe a projection model for COVID-19 cases in Sri Lanka applied to different scenarios after lockout, utilizing the stringency index as a proxy of total government response. Methods COVID-19 Stringency Index (C19SI) is published and updated real time by a research group from Oxford university on 17 selected mitigation and suppression measures employed by different countries. We have mapped and validated the stringency index for Sri Lanka and subsequently validated the projection model in two phases. Predictions for the base-case scenario, less stringent scenarios, advanced relaxation scenarios, and high-risk districts were done with 95% confidence intervals (95%CI) using the validated model, utilizing data up to 10th May. Results C19SI was able to accommodate all of the government responses. The model using validated C19SI could predict number of cases with 95% confidence for a period of two weeks. The model predicted base-case scenario of 815 (95%CI, 753-877) active cases by 17 May 2020 and 648 (95%CI, 599-696) cases for the high-risk districts by 18 May 2020. The model further predicted 3,159 (95%CI, 2,928-3,391) cases for 75% stringency and 928,824 (95%CI, 861,772-995,877) cases for 50% stringency. Advancing normalcy by three weeks resulted in the case load increasing to 4526 (95%CI, 4309-4744) by 30 June 2020. Conclusion The proposed prediction model based on C19SI provides policy makers an evidence based scientific method for identifying suppression measures that can be relaxed at the most appropriate time. Key words: COVID-19, Projections, Stringency Index, SIR Model, Sri Lanka
- Open Access
AN EPIDEMIOLOGICAL MODEL TO AID DECISION-MAKING FOR COVID-19 CONTROL IN SRI LANKA
Background: Sri Lanka diagnosed its first local case of COVID-19 on 11 March 2020. The government acted swiftly to contain transmission, with extensive public health measures. At the end of 30 days, Sri Lanka had 197 cases, 54 recovered and 7 deaths; a staged relaxing of the lockdown is now underway. This paper proposes a theoretical basis for estimating the limits within which transmission should be constrained in order to ensure that the case load remains within the capacity of the health system. Methods: We used Susceptible, Infected, Recovered model to estimate the ICU bed requirement at different levels of R 0 values after lockout. We developed a web application that enables visualization of cases and ICU bed requirements with time, with adjustable parameters that include: population exposed; proportion asymptomatic; number of active and recovered cases; infectious period; R 0 or doubling time; proportion critically ill; available ICU beds and duration of ICU stay. Results: The three-day moving average of the caseload suggested two waves of transmission from Day 0 to 17 (R 0 =3.32, 95% CI 1.85 - 5.41) and from Day 18 - 30 (R=1.25, 95%CI: 0.93 - 1.63). We estimate that if there are 156 active cases with 91 recovered at the time of lockout, and R increases to 1.5 (doubling time 19 days), under the standard parameters for Sri Lanka, the ICU bed capacity of 300 is likely to be saturated by about 100 days, signalled by 18 new infections (95% CI 15 - 22) on Day 14 after lockout. Conclusion: Our model suggests that to ensure that the case load remains within the available capacity of the health system after lockout, transmission should not exceed R=1.5. This model and the web-based application may be useful in other low- and middle-income countries which have similar constraints on health resources.
Open AccessAN EPIDEMIOLOGICAL MODEL TO AID DECISION-MAKING FOR COVID-19 CONTROL IN SRI LANKA
Background: Sri Lanka diagnosed its first local case of COVID-19 on 11 March 2020. The government acted swiftly to contain transmission, with extensive public health measures. At the end of 30 days, Sri Lanka had 197 cases, 54 recovered and 7 deaths; a staged relaxing of the lockdown is now underway. This paper proposes a theoretical basis for estimating the limits within which transmission should be constrained in order to ensure that the case load remains within the capacity of the health system. Methods: We used Susceptible, Infected, Recovered model to estimate the ICU bed requirement at different levels of R 0 values after lockout. We developed a web application that enables visualization of cases and ICU bed requirements with time, with adjustable parameters that include: population exposed; proportion asymptomatic; number of active and recovered cases; infectious period; R 0 or doubling time; proportion critically ill; available ICU beds and duration of ICU stay. Results: The three-day moving average of the caseload suggested two waves of transmission from Day 0 to 17 (R 0 =3.32, 95% CI 1.85 - 5.41) and from Day 18 - 30 (R=1.25, 95%CI: 0.93 - 1.63). We estimate that if there are 156 active cases with 91 recovered at the time of lockout, and R increases to 1.5 (doubling time 19 days), under the standard parameters for Sri Lanka, the ICU bed capacity of 300 is likely to be saturated by about 100 days, signalled by 18 new infections (95% CI 15 - 22) on Day 14 after lockout. Conclusion: Our model suggests that to ensure that the case load remains within the available capacity of the health system after lockout, transmission should not exceed R=1.5. This model and the web-based application may be useful in other low- and middle-income countries which have similar constraints on health resources.
- Open Access
- 6 December 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 142
Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology – a prospective study
Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC). The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear. Patients with nvHCC, referred to a Hepatobiliary Clinic from September 2011–2015 were screened. HCC was diagnosed using American Association for the Study of Liver Disease guidelines, and TNM staged. nvHCC was diagnosed when HBsAg and anti-HCVAb was negative. Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated. AFP level was evaluated against patient characteristics, tumour characteristics and survival. Three hundred eighty-nine patients with nvHCC [age 64(12–88) years; 344(88.4%) males] were screened. Median AFP was 25.46 ng/ml (1.16–100,000). 41.2% (n = 160) Of patients had normal AFP level. 22.9% (n = 89) had AFP over 400 ng/ml. Female gender (P < 0.05), vascular invasion (P < 0.001), tumours over 5 cm (P < 0.05), late TNM stage (P < 0.001) and non-surgical candidates had higher AFP levels. Diffuse type (P < 0.001), macro vascular invasion (P < 0.001) and late stage tumours (P < 0.001) had AFP over 400 ng/ml. Having AFP below 400 ng/ml was associated with longer survival (16 vs. 7 months, P < 0.001). Pre treatment AFP has a limited value In diagnosing nvHCC, Having a AFP value over 400 ng/ml was associated with aggressive tumour behaviour and poor prognosis.
- 6 December 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 142
Open AccessPre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology – a prospective study
Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC). The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear. Patients with nvHCC, referred to a Hepatobiliary Clinic from September 2011–2015 were screened. HCC was diagnosed using American Association for the Study of Liver Disease guidelines, and TNM staged. nvHCC was diagnosed when HBsAg and anti-HCVAb was negative. Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated. AFP level was evaluated against patient characteristics, tumour characteristics and survival. Three hundred eighty-nine patients with nvHCC [age 64(12–88) years; 344(88.4%) males] were screened. Median AFP was 25.46 ng/ml (1.16–100,000). 41.2% (n = 160) Of patients had normal AFP level. 22.9% (n = 89) had AFP over 400 ng/ml. Female gender (P < 0.05), vascular invasion (P < 0.001), tumours over 5 cm (P < 0.05), late TNM stage (P < 0.001) and non-surgical candidates had higher AFP levels. Diffuse type (P < 0.001), macro vascular invasion (P < 0.001) and late stage tumours (P < 0.001) had AFP over 400 ng/ml. Having AFP below 400 ng/ml was associated with longer survival (16 vs. 7 months, P < 0.001). Pre treatment AFP has a limited value In diagnosing nvHCC, Having a AFP value over 400 ng/ml was associated with aggressive tumour behaviour and poor prognosis.